The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2024
year mood +0.08 · -0.20 to +0.30 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan +0.30 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec -0.20
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.30+0.20+0.30+0.10+0.10+0.20+0.10+0.07+0.00-0.10-0.10-0.20

GLP-1 leaders (Lilly hitting record value) kept me euphoric early, but managed care melted down under Medicare Advantage rate cuts and rising medical costs, the Change Healthcare cyberattack disrupted the system, and Medicare's first negotiated drug prices bit;

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2024
Aug
Biden Administration Announces First Medicare Drug Prices, Projecting $6B in Savings cnbc.com →

The Biden administration revealed negotiated prices for 10 high-cost Medicare drugs, projecting $6 billion in savings for the program and $1.5 billion in out-of-pocket savings for enrollees by 2026. The move, enabled by the Inflation Reduction Act, marks a shift in U.S. drug pricing policy, setting a precedent for future negotiations with major pharmaceutical companies including Merck, Eli Lilly, and Johnson & Johnson. While patient advocates applaud the effort, the industry warns of reduced innovation and ongoing legal challenges.